BC Extra | Oct 30, 2019
Politics & Policy

Cuccinelli accepts responsibility for decision to deport patients

Ken Cuccinelli, acting director of U.S. Citizenship and Immigration Services, Wednesday took responsibility for the Trump administration’s August 2019 decision to initiate deportation proceedings against critically ill patients and their families. Cuccinelli testified to the...
BC Extra | Sep 20, 2019
Politics & Policy

Administration reverses policy decision on deferred action for patients

Under intense public pressure, the Trump administration has reversed course on how it handles requests to defer deportations for medical reasons, taking the decisions out of the hands of ICE and giving them back to...
BC Extra | Sep 11, 2019
Politics & Policy

Few answers from hearing on medical deferred action

Testifying Wednesday at a congressional hearing, Trump administration officials were unable to explain why hundreds of people with life-threatening conditions have been threatened with deportation. The House Committee on Oversight and Reform’s subcommittee on civil...
BC Extra | Sep 4, 2019
Politics & Policy

U.S. reconsidering deportation orders for patients receiving medical treatment

Following a media firestorm and outcry from patient groups and biopharma executives, the Trump administration has said it will reconsider a policy change that could lead to the deportations of a rare disease patient and...
BC Extra | Aug 30, 2019
Politics & Policy

Biotech leaders outraged by planned deportation of rare disease patient

Biotech industry leaders have expressed outrage at reports that a patient who is receiving a life-saving therapy in the U.S. that is unavailable in her country is facing the threat of deportation. Media reports indicate...
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio...
BC Week In Review | Oct 5, 2015
Company News

BioMarin, Serono deal

BioMarin will regain rights to phenylketonuria (PKU) treatments Kuvan sapropterin dihydrochloride and pegvaliase ( BMN 165 ) from the Merck Serono S.A. unit of Merck KGaA (Xetra:MRK, Darmstadt, Germany). Merck held ex-U.S. and Japan rights to Kuvan...
BC Extra | Oct 2, 2015
Company News

BioMarin buys back PKU franchise from Merck Serono

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) regained rights to phenylketonuria (PKU) treatments Kuvan sapropterin dihydrochloride and pegvaliase ( BMN 165 ) from the Merck Serono S.A. unit of Merck KGaA (Xetra:MRK). Merck held ex-U.S. and Japan rights to Kuvan...
BC Extra | Aug 4, 2015
Company News

BioMarin revenues rise as it awaits DMD meeting

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported earnings and said it is planning an early 2016 launch for drisapersen , its therapy for Duchenne muscular dystrophy amenable to exon 51 skipping. The antisense oligoribonucleotide that induces exon 51...
BC Extra | Mar 28, 2015
Top Story

BioMarin rises on takeout rumors

Rare disease company BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) jumped $13.23 (11%) to $128.78 on Friday, ending the day with a market cap of $20.5 billion, amid rumors that Shire plc (LSE:SHP; NASDAQ:SHPG) has approached it with...
Items per page:
1 - 10 of 124